Antisense oligonucleotides for modulating htra1 expression
OwnerRubén Alvarez Sánchez, Roberto Iacone +8inventors
InventorsRubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
Claims23
An antisense oligonucleotide of 10-30 nucleotides in length, wherein said antisense oligonucleotide targets a HTRA1 nucleic acid, and comprises a contiguous nucleotide region of 10-22 nucleotides which are at least 90% such as 100% complementarity to SEQ ID NO 113.
An oligonucleotide comprising or consisting of an oligonucleotide selected from the group consisting of:
- (SEQ ID NO 67.1)
- TsTsmCstsastscstsasmcsgscsasTsTsG,
- (SEQ ID NO 73.1)
- mCsTsTsmCststscstsastscstsasmcsgscsAsT,
- and
- (SEQ ID NO 86.1)
- TsAsmCsTststsasastsasgscsTsmCsAsA;
- wherein capital letters represent beta-D-oxy LNA nucleosides, lower case letters are DNA nucleosides, subscript s represents a phosphorothioate internucleoside linkage, and mC represent 5 methyl cytosine beta-D-oxy LNA nucleosides, and mc represents 5 methyl cytosine DNA nucleosides.
Dependencies are inferred from the claim text.